GlassScriptPhysician profile
Weiguo Zhao
NPI 1649260134
$5,314.18
in general payments reported to CMS, 2019-2025
35 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,099 · 2020: $403 · 2021: $735 · 2022: $837 · 2023: $761 · 2024: $950 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,210 · Education: $29.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,210.34 |
| Education | $29.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $841.54 | 2019-2025 | Mavenclad |
| Neurelis, INC. | $657.70 | 2020-2025 | Valtoco |
| Biogen, INC. | $546.31 | 2019-2025 | Vumerity, Avonex, Tysabri |
| Neurocrine Biosciences, INC. | $515.96 | 2019-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $364.31 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $353.11 | 2019-2023 | Austedo Xr |
| Eisai INC. | $209.39 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $199.18 | 2019-2021 | |
| Sk Life Science, INC. | $171.04 | 2021-2024 | |
| Lilly USA, LLC | $168.55 | 2019-2022 | |
| Aucta Pharmaceuticals, INC. | $143.75 | 2024-2025 | Motpoly Xr |
| Celgene Corporation | $122.36 | 2022-2023 | Zeposia |
| Genentech USA, INC. | $106.99 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $105.99 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $86.05 | 2022-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $75.30 | 2019-2021 | |
| Corium, LLC | $74.72 | 2023 | Adlarity |
| Harmony Biosciences LLC | $65.09 | 2021-2022 | |
| Kyowa Kirin, INC. | $60.85 | 2019-2021 | |
| Amgen INC. | $58.97 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $49.45 | 2019 | |
| Abbvie INC. | $45.80 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $44.46 | 2023 | Aptiom |
| Astellas Pharma US INC | $40.79 | 2022 | |
| Janssen Pharmaceuticals, INC | $30.51 | 2022 | |
| Adamas Pharmaceuticals, INC. | $23.57 | 2019 | |
| Lundbeck LLC | $20.59 | 2022 | |
| Pfizer INC. | $18.41 | 2025 | |
| Greenwich Biosciences, INC. | $17.46 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $16.72 | 2024 | |
| Amneal Pharmaceuticals LLC | $16.57 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.00 | 2020 | |
| Genzyme Corporation | $15.92 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.77 | 2021 | |
| Allergan, INC. | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weiguo Zhao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.